A Phase 1/2 interventional study of BAY3427080 and Placebo (for BAY3427080) in Post-menopausal Vasomotor Symptoms, sponsored by Bayer. Completed at 3 sites in United States. Open to female participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-07.
Sponsored by Bayer · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.
Among the 13 studies testing elinzanetant in Hot Flashes, this one is the 6th largest by enrollment, is the only one that started in 2016, is the only one in phase 1/2, and was the 1st registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →
elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 45 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 2 · Phase 3 4
First in 2016; this study’s year is marked. 1 started in 2016.
This study's enrollment of 76 is below the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 64 across the 13 interventional studies. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 1 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
18 studies in Hot Flashes by Bayer: none open now, 1 under way, 1 of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 18 studies in Hot Flashes by Bayer, this one is the 11th largest by enrollment, is the only one that started in 2016, is the only one in phase 1/2, and was the 6th registered.
Bayer’s Hot Flashes studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing elinzanetant in Hot Flashes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 18 in Hot Flashes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts. Each cohort will comprise of 20 subjects. Subjects will be dosed for 14 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
female subjects experiencing frequent moderate to severe hot flashes.Menopause will be defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo (for BAY3427080)
Drug: BAY3427080
Drug: BAY3427080
Drug: BAY3427080
Drug: BAY3427080
Also known as: NT-814
Maximum Observed Plasma Concentration (Cmax) of BAY3427080
Cmax is the maximum observed plasma concentration of BAY3427080 was presented. Blood samples were taken within 30 minutes prior to dose administration.
Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
Time to Reach Maximum Observed Drug Concentration in Plasma (Tmax) of BAY3427080
Time of occurrence of Cmax.Time to reach maximum plasma concentration of BAY3427080 was presented. Blood samples for Tmax were taken within 30 minutes prior to dose administration.
Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of BAY3427080
AUC from time zero extrapolated to infinity of BAY3427080 was presented. AUC0-∞ was only estimated following the Day 1 dose.
Time frame: Day 1 (pre-dose and post-dose (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 12.0 and 24.0 hours)
Area Under the Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-τ) of BAY3427080
Area under the concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration of BAY3427080 was presented. Blood samples for (AUC0-τ) were taken within 30 minutes prior to dose administration.
Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
Terminal Elimination Half-life (t½) of BAY3427080
Terminal elimination half-life of BAY3427080 was presented. Blood samples were taken within 30 minutes prior to dose administration.
Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
Apparent Clearance (CL/F) of BAY3427080
Apparent clearance of BAY3427080 was presented. Blood samples were taken within 30 minutes prior to dose administration.
Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
Number of Participants With Clinically Significant Abnormalities Detected Upon Physical Examination.
A physician or appropriately qualified delegate conducted a full physical examination. Clinically significance was decided by investigator. The findings are presented as abnormal (clinically significant).
Time frame: At day 14
Number of Participants With Clinically Significant Abnormalities on the 12-lead ECGs
Reported results are cardiovascular system-examination findings at day 14. Clinically significance was decided by investigator. The findings are presented as abnormal (clinically significant).
Time frame: At day 14
Number of Participants With Arrhythmias as Assessed by Continuous Holter Monitoring.
Holter monitors were supplied by iCardiac Technologies. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14 and remained in place until 24-hour assessments were completed.
Time frame: Baseline (day -1) and day 14
Change From Baseline at Day 14 in Vital Signs: Diastolic Blood Pressure (Standing)
Diastolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in standing position.
Time frame: Baseline and day 14
Change From Baseline at Day 14 in Vital Signs: Diastolic Blood Pressure (Sitting)
Diastolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in sitting position.
Time frame: Baseline and day 14
Change From Baseline at Day 14 in Vital Signs: Systolic Blood Pressure (Standing)
Systolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in standing position.
Time frame: Baseline and day 14
Change From Baseline at Day 14 in Vital Signs: Systolic Blood Pressure (Sitting)
Systolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in sitting position.
Time frame: Baseline and day 14
Change From Baseline at Day 14 in Vital Signs: Pulse Rate
Pulse rate was measured just prior to dosing (approx. 30 mins).
Time frame: Baseline and day 14
Change From Baseline at Day 14 in Vital Signs: Respiratory Rate
Respiratory rate was measured just prior to dosing (approx. 30 mins).
Time frame: Baseline and day 14
Change From Baseline at Day 14 in Vital Signs: Oxygen Saturation
Oxygen Saturation was measured just prior to dosing (approx. 30 mins).
Time frame: Baseline and day 14
Change From Baseline at Day 14 in Vital Signs: Oral Body Temperature
Temperature was measured just prior to dosing (approx. 30 mins).
Time frame: Baseline and day 14
Change From Baseline at Day 14 in Vital Signs: Weight
Weight was measured just prior to dosing (approx. 30 mins).
Time frame: Baseline and day 14
Change From Baseline at Day 15 for Laboratory Hormones Results : Adrenocorticotropic Hormone (ADTH) and Estradiol.
Blood samples for the assessment of ACTH and Estradiol were collected upon participants admission to the unit.
Time frame: Baseline and day 15
Change From Baseline at Day 15 for Laboratory Hormones Results: Follicle Stimulating Hormone
Blood samples for the assessment of Follicle Stimulating were collected upon participants admission to the unit.
Time frame: Baseline and day 15
Change From Baseline at Day 15 for Laboratory Hormones Results : Triiodothyronine Uptake
Blood samples for the assessment of Triiodothyronine were collected upon participants admission to the unit.
Time frame: Baseline and day 15
Change From Baseline at Day 15 for Laboratory Hormones Results: Thyrotropin
Blood samples for the assessment of Thyrotropin were collected upon participants admission to the unit.
Time frame: Baseline and day 15
Change From Baseline at Day 15 for Laboratory Hormones Results : Cortisol, Testosterone, Thyroxine and Triiodothyronine
Blood samples for the assessment of Cortisol, Testosterone, Thyroxine and Triiodothyronine were collected upon participants admission to the unit.
Time frame: Baseline and day 15
Change From Baseline at Day 14 for Clinical Laboratory Parameters LIPIDS : Cholesterol, Triglycerides, HDL Cholesterol and LDL Cholesterol.
Blood samples for the assessment of Cholesterol, Triglycerides,high-density lipoprotein (HDL)Cholesterol and low-density lipoprotein (LDL) Cholesterol were collected upon participants admission to the unit.
Time frame: Baseline and day 14
Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils and Immature Granulocytes.
Blood samples for the assessment of Neutrophils/Leukocytes, Lymphocytes /Leukocytes, Monocytes/Leukocytes, Eosinophils/Leukocytes, Basophils/Leukocytes and Immature Granulocytes/ Leukocytes were collected upon participants admission to the unit.
Time frame: Baseline and day 14
Change From Baseline at Day 14 for Clinical Laboratory Parameters HEMATOLOGY: Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Immature Granulocytes and Platelets.
Blood samples for the assessment of Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Immature Granulocytes and Platelets were collected upon participant's admission to the unit.
Time frame: Baseline and day 14
Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin Concentration
Blood samples for the assessment of Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HB)concentration were collected upon participants admission to the unit.
Time frame: Baseline and day 14
Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes
Blood samples for the assessment of Erythrocytes were collected upon participants admission to the unit.
Time frame: Baseline and day 14
Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Mean Corpuscular Volume and Mean Platelet Volume.
Blood samples for the assessment of Erythrocytes Mean Corpuscular Volume and Mean Platelet Volume were collected upon participants admission to the unit.
Time frame: Baseline and day 14
Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Mean Corpuscular Hemoglobin
Blood samples for the assessment of Erythrocytes Mean Corpuscular Hemoglobin were collected upon participants admission to the unit.
Time frame: Baseline and day 14
Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Distribution Width.
Blood samples for the assessment of Erythrocytes Distribution Width were collected upon participants admission to the unit. Erythrocytes distribution width (in percentage) = 1 SD of Erythrocyte volume/MCV x 100%
Time frame: Baseline and day 14
Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Hematocrit.
Blood samples for the assessment of Hematocrit were collected upon participants admission to the unit.
Time frame: Baseline and day 14
Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Protein and Albumin.
Blood samples for the assessment of Protein and Albumin were collected upon participants admission to the unit.
Time frame: Baseline and day 14
Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Creatine Kinase
Blood samples for the assessment of Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Creatine Kinase were collected upon participants admission to the unit.
Time frame: Baseline and day 14
Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Urate, Bilirubin and Creatinine.
Blood samples for the assessment of Urate, Bilirubin and Creatinine were collected upon participants admission to the unit.
Time frame: Baseline and day 14
Change From Baseline at Day 14 for Clinical Laboratory Parameters CHEMISTRY: Sodium, Potassium, Chloride, Bicarbonate, Calcium, Phosphate, Glucose, Magnesium and Urea Nitrogen.
Blood samples for the assessment of Sodium, Potassium, Chloride, Bicarbonate, Calcium, Phosphate, Glucose, Magnesium and Urea Nitrogen were collected upon participant's admission to the unit.
Time frame: Baseline and day 14
Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate African at Baseline
Blood samples for the assessment of Glomerular Filtration Rate African were collected upon participants admission to the unit.
Time frame: At Baseline
Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate Caucasian at Baseline
Blood samples for the assessment of Glomerular Filtration Rate Caucasian were collected upon participants admission to the unit.
Time frame: At Baseline
Change From Baseline at Day 14 for COAGULATION: Prothrombin International Normalized Ratio (INR)
Blood samples for the assessment of Prothrombin International Normalized Ratio were collected upon participants admission to the unit.
Time frame: Baseline and day 14
Change From Baseline at Day 14 for COAGULATION: Prothrombin Time and Activated Partial Thromboplastin Time
Blood samples for the assessment of Prothrombin Time and Activated Partial Thromboplastin Time were collected upon participants admission to the unit.
Time frame: Baseline and day 14
Heart Rate (HR) - Change From Baseline (Day -1) at Day 14
Heart rate was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made.Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.
Time frame: Baseline (day -1) and day 14
Mean PR Interval - Change From Baseline (Day -1) at Day 14
PR Interval was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.
Time frame: Baseline (day -1) and day 14
Mean QRS Duration - Change From Baseline (Day -1) at Day 14
QRS Duration was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.
Time frame: Baseline (day -1) and day 14
Mean QT Interval - Change From Baseline (Day -1) at Day 14
QT Interval was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.
Time frame: Baseline (day -1) and day 14
Mean QTcF Interval (Fridericia's Correction Formula, QTcF) - Change From Baseline (Day -1) at Day 14
Fridericia-corrected QTcF interval was evaluated as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.
Time frame: Baseline (day -1) and day 14
Mean QTcB Interval (Bazett's Correction Formula, QTcB) - Change From Baseline (Day -1) at Day 14
Bazett-corrected QTcB interval was evaluated as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.
Time frame: Baseline (day -1) and day 14
Nature and Severity of Adverse Events (AEs) up to Day 21
An AE was defined as any untoward medical occurrence in a subject or clinical trial subject administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product. Serious Adverse Event (SAE) is an adverse event that at any dose: Results in death, Is life-threatening (i.e. the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe), Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is considered to be an important medical event.
Time frame: On or after first drug administration up to end of study (Day 21).
Withdrawals Due to AEs up to Day 21
An AE was defined as any untoward medical occurrence in a subject or clinical trial subject administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product. Serious Adverse Event (SAE) is an adverse event that at any dose: Results in death, Is life-threatening (i.e. the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe), Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is considered to be an important medical event.
Time frame: On or after first drug administration up to end of study (Day 21)
Change in Frequency of Hot Flushes From Baseline (Day -1) at Days 7, 14 as Assessed by Skin Conductance
Sternal skin conductance monitors (the Bahr MonitorTM) and the associated algorithm software were supplied by Simplex Scientific LLC (Middleton, USA). Participants were instructed to push a button on the skin conductance monitor when they sensed a hot flush when fitted with the monitor and then provide details of the hot flush in the continuous hot flush diary. Sternal skin conductance monitors were fitted on Day -1 (24 hours±1 hour prior to the planned study drug administration on Day 1) and remained in place until after the Day 7 24-hour assessments were completed (on Day 8). Refitted around 30 minutes prior to study drug administration on Day 14 and remained in place until after the 24-hour assessments were completed on Day 15.
Time frame: Baseline (day -1) and days 7, 14
Change From Baseline (Week -1) at Weeks 1, 2 in Frequency of Moderate to Severe Hot Flushes as Measured by Twice Daily Paper Diary Throughout Study
Hot flush frequency and hot flush severity were obtained using the Hot Flush paper Diary. Subjects documented the number of individual hot flushes experienced and rated the severity of each on a scale of 1 to 3 (mild = 1, moderate = 2, severe = 3). The diaries were completed based on recall twice daily, in the morning and evening.
Time frame: Baseline (week -1) and Week 1 ,Week 2
Change From Baseline (Week -1) at Weeks 1, 2 in Average Daily Severity of Hot Flushes as Measured by Twice Daily Paper Diary
Participants documented the number of individual hot flushes experienced and rated the severity of each on a scale of 1 to 3 (mild = 1, moderate = 2, severe = 3). The diaries were completed based on recall twice daily, in the morning and evening.
Time frame: Baseline (week -1) and weeks 1, Week 2
Change From Baseline (Week -1) at Weeks 1, 2 in Average Daily Hot Flushes Severity Score as Measured by Twice Daily Paper Diary.
The hot flushes severity score was a composite of the frequency and severity of hot flushes, and was calculated as follows: number of mild hot flushes recorded on Day Y + number of moderate hot flushes recorded on Day Y × 2 + number of severe hot flushes recorded on Day Y × 3. Higher scores mean more severe hot flushes.
Time frame: Baseline (week -1) and week 1 , 2
Change in Frequency From Baseline (Day -1), at Days 7, 14 of Hot Flushes as Measured by Continuous Day Time Diary.
Subjects recorded each hot flush and its severity on a scale of 1 to 3 (mild = 1, moderate = 2, severe = 3) in the hot flush paper diary as they occurred during the day and night.
Time frame: Baseline(day -1) and Day 7, 14
Change From Baseline (Week -1) at Weeks 1, 2 in Night-time Awakenings (NTA) Secondary to Hot Flushes as Measured by Paper Diary
The number of NTAs secondary to hot flushes was the sum of the number of moderate and severe night-time hot flushes recorded the following morning (twice-daily hot flush diary) or recorded contemporaneously on the continuous diary.
Time frame: Baseline (week-1) and weeks 1 , 2
Change From Baseline (Day-1) to Day 1 and Day 7 in Luteinizing Hormone (AUC0-8)
Change in Luteinizing Hormone(LH) AUC from time zero to 8 hours. Pre-dose samples for LH were taken within 30 minutes prior to dose administration.
Time frame: baseline (day-1) to day 1 and day 7, pre-dose and post-dose (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 12.0 and 24.0 hours)
The study was conducted between 01 August 2016 (first subject, screening visit) and 28 March 2017 (last subject, last visit).
| Milestone | Placebo Comparator | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg of BAY3427080 |
|---|---|---|---|---|---|
| Started | 18 | 15 | 15 | 15 | 13 |
| Completed | 17 | 15 | 14 | 15 | 13 |
| Not completed | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
Cmax is the maximum observed plasma concentration of BAY3427080 was presented. Blood samples were taken within 30 minutes prior to dose administration.
| ng/mL | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Day 1 | — | 502.62 ± 90.19 | 731.69 ± 110.58 | 911.48 ± 148.28 | 1576.01 ± 90.70 |
| Day 7 | — | 548.60 ± 57.47 | 809.48 ± 116.58 | 1173.50 ± 95.14 | 2045.61 ± 152.87 |
| Day 14 | — | 522.36 ± 87.88 | 841.42 ± 107.16 | 1188.19 ± 131.20 | 2851.83 ± 116.53 |
Time of occurrence of Cmax.Time to reach maximum plasma concentration of BAY3427080 was presented. Blood samples for Tmax were taken within 30 minutes prior to dose administration.
| hr | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Day 1 | — | 1.360 ± 40.01 | 1.320 ± 38.79 | 1.521 ± 41.95 | 1.471 ± 63.05 |
| Day 7 | — | 1.432 ± 39.25 | 1.623 ± 43.19 | 1.536 ± 40.08 | 1.754 ± 56.18 |
| Day 14 | — | 1.265 ± 46.32 | 1.445 ± 56.71 | 1.296 ± 23.35 | 1.342 ± 33.46 |
AUC from time zero extrapolated to infinity of BAY3427080 was presented. AUC0-∞ was only estimated following the Day 1 dose.
| hr*ng/mL | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of BAY3427080 | — | 2018.68 ± 38.43 | 1545.58 ± 3.49 | 1151.87 ± 66.73 | 6249.52 ± 101.01 |
Area under the concentration-time curve (AUC) from time zero to the time of the last quantifiable concentration of BAY3427080 was presented. Blood samples for (AUC0-τ) were taken within 30 minutes prior to dose administration.
| hr*ng/mL | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Day 1 | — | 1400.167 ± 67.87 | 2341.882 ± 71.19 | 3012.793 ± 97.74 | 6527.569 ± 70.50 |
| Day 7 | — | 2506.97 ± 48.05 | 4472.76 ± 63.83 | 6202.894 ± 43.92 | 12859.660 ± 85.47 |
| Day 14 | — | 2341.55 ± 64.73 | 3542.41 ± 86.34 | 5163.500 ± 88.71 | 14822.860 ± 99.68 |
Terminal elimination half-life of BAY3427080 was presented. Blood samples were taken within 30 minutes prior to dose administration.
| hr | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Day 1 | — | 2.409 ± 34.15 | 1.903 ± 11.98 | 3.965 ± 45.94 | 3.142 ± 18.92 |
| Day 7 | — | 2.443 ± 9.33 | 3.303 ± 21.20 | 3.482 ± 22.57 | 2.271 |
| Day 14 | — | 2.698 ± 21.64 | 2.042 | 21.593 ± 24.58 | 20.427 ± 22.85 |
Apparent clearance of BAY3427080 was presented. Blood samples were taken within 30 minutes prior to dose administration.
| L/hr | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Day 1 | — | 24.769 ± 38.43 | 64.700 ± 3.49 | 130.223 ± 66.73 | 48.004 ± 101.01 |
| Day 7 | — | 19.944 ± 48.05 | 22.358 ± 63.83 | 24.182 ± 43.92 | 23.329 ± 85.47 |
| Day 14 | — | 21.353 ± 64.73 | 28.229 ± 86.34 | 29.050 ± 88.71 | 20.239 ± 99.68 |
A physician or appropriately qualified delegate conducted a full physical examination. Clinically significance was decided by investigator. The findings are presented as abnormal (clinically significant).
| Participants | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities Detected Upon Physical Examination. | 1 | 0 | 2 | 1 | 2 |
Reported results are cardiovascular system-examination findings at day 14. Clinically significance was decided by investigator. The findings are presented as abnormal (clinically significant).
| Participants | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities on the 12-lead ECGs | 0 | 0 | 1 | 0 | 0 |
Holter monitors were supplied by iCardiac Technologies. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14 and remained in place until 24-hour assessments were completed.
| Participants | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Average Hourly Daytime Heart Rate < 50 bpm (daytime defined as 7 am-10 pm)(Day-1) | 0 | 0 | 1 | 0 | 0 |
| Frequent Supraventricular Premature Beats (APBs) (>100/24hrs) (Day-1) | 2 | 1 | 3 | 0 | 0 |
| Frequent Ventricular Ectopic Beats (VEs) (> 200/24hrs) (Day-1) | 1 | 4 | 1 | 0 | 2 |
| Other arrhythmias (Day-1) | 17 | 13 | 15 | 15 | 12 |
| Second Degree AV Block - Type I (Day-1) | 1 | 0 | 0 | 0 | 0 |
| Sinus Bradycardia (HR < 40 bpm)(Day-1) | 0 | 0 | 1 | 0 | 0 |
| SupraVentricular Tachycardia (lasting > 10 beats) (Day-1) | 4 | 5 | 4 | 2 | 1 |
| At least three monomorphic beats in a row (Day 14) | 0 | 0 | 0 | 1 | 0 |
| Average Hourly Daytime Heart Rate < 50 bpm (daytime defined as 7 am-10 pm) (Day 14) | 0 | 0 | 0 | 0 | 1 |
| Frequent Supraventricular Premature Beats (APBs) (>100/24hrs) (Day 14) | 1 | 0 | 0 | 0 | 0 |
| Frequent Ventricular Ectopic Beats (VEs) (> 200/24hrs) (Day 14) | 1 | 4 | 0 | 0 | 1 |
| Other arrhythmias (Day 14) | 18 | 14 | 13 | 15 | 13 |
| Presence of NSVT (Non-Sustained Ventricular Tachycardia) episodes (Day 14) | 0 | 0 | 0 | 1 | 0 |
| Second Degree AV Block - Type I (Day 14) | 2 | 0 | 0 | 0 | 0 |
| Second Degree AV Block - Type II(Day 14) | 1 | 0 | 0 | 1 | 0 |
| Sinus Bradycardia (HR < 40 bpm) | 0 | 0 | 0 | 1 | 0 |
| SupraVentricular Tachycardia (lasting > 10 beats (Day 14) | 3 | 3 | 1 | 1 | 1 |
Diastolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in standing position.
| mmHg | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 80.11 ± 4.702 | 76.07 ± 5.257 | 77.67 ± 11.462 | 78.93 ± 6.147 | 77.92 ± 9.768 |
| Day 14 Change from Baseline | 1.11 ± 9.579 | 2.53 ± 5.540 | -0.07 ± 12.137 | 0.93 ± 7.216 | 1.62 ± 9.097 |
Diastolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in sitting position.
| mmHg | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 77.72 ± 6.542 | 74.27 ± 6.239 | 77.20 ± 10.705 | 74.80 ± 6.774 | 74.15 ± 8.245 |
| Day 14 Change from Baseline | 0.11 ± 9.292 | -0.53 ± 6.906 | -0.79 ± 9.736 | 2.73 ± 9.384 | 1.77 ± 6.366 |
Systolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in standing position.
| mmHg | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 117.83 ± 10.733 | 114.60 ± 8.675 | 121.33 ± 17.867 | 118.87 ± 11.513 | 114.77 ± 15.095 |
| Day 14 Change from Baseline | 5.11 ± 11.483 | 3.80 ± 13.311 | -4.43 ± 18.744 | 0.33 ± 12.234 | 5.62 ± 16.536 |
Systolic Blood Pressure was measured just prior to dosing (approx. 30 mins) in sitting position.
| mmHg | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 116.39 ± 11.304 | 113.80 ± 9.405 | 119.07 ± 15.931 | 117.20 ± 10.638 | 114.15 ± 14.288 |
| Day 14 Change from Baseline | 4.17 ± 11.868 | 0.20 ± 10.359 | -2.79 ± 16.470 | 2.47 ± 16.890 | 5.62 ± 12.672 |
Pulse rate was measured just prior to dosing (approx. 30 mins).
| beats/min | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 69.89 ± 8.629 | 66.00 ± 6.358 | 69.20 ± 9.966 | 68.40 ± 4.611 | 72.62 ± 7.136 |
| Day 14 Change from Baseline | 1.06 ± 8.271 | -2.00 ± 8.027 | 0.14 ± 7.263 | 0.27 ± 8.388 | -11.00 ± 9.618 |
Respiratory rate was measured just prior to dosing (approx. 30 mins).
| breaths/min | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 15.39 ± 1.378 | 15.47 ± 1.727 | 15.73 ± 1.624 | 15.60 ± 1.502 | 15.85 ± 1.573 |
| Day 14 Change from Baseline | -0.11 ± 2.220 | -0.40 ± 2.197 | 0.07 ± 1.940 | -0.43 ± 2.065 | -1.33 ± 1.923 |
Oxygen Saturation was measured just prior to dosing (approx. 30 mins).
| Percentage of Oxygen satuartion | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 98.50 ± 1.098 | 98.40 ± 1.404 | 97.87 ± 1.727 | 97.67 ± 1.496 | 97.31 ± 1.251 |
| Day 14 Change from Baseline | -0.61 ± 1.539 | -0.73 ± 1.486 | 0.29 ± 2.091 | 0.20 ± 1.424 | 0.38 ± 1.193 |
Temperature was measured just prior to dosing (approx. 30 mins).
| Degree Celius | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 36.77 ± 0.190 | 36.65 ± 0.155 | 36.79 ± 0.162 | 36.71 ± 0.168 | 36.77 ± 0.361 |
| Day 14 Change from Baseline | -0.04 ± 0.243 | 0.06 ± 0.172 | -0.09 ± 0.264 | -0.01 ± 0.239 | -0.05 ± 0.458 |
Weight was measured just prior to dosing (approx. 30 mins).
| Kilograms | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 73.25 ± 10.115 | 70.85 ± 11.821 | 73.47 ± 14.934 | 72.10 ± 7.104 | 72.73 ± 12.047 |
| Day 14 Change from Baseline | 0.36 ± 1.034 | 0.51 ± 0.983 | 0.24 ± 0.916 | 0.15 ± 0.926 | 0.01 ± 0.704 |
Blood samples for the assessment of ACTH and Estradiol were collected upon participants admission to the unit.
| pmol/L | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline (ADTH) | 5.34 ± 3.402 | 4.17 ± 1.991 | 3.87 ± 2.361 | 3.55 ± 2.360 | 3.27 ± 2.011 |
| Day 15 Change from Baseline (ADTH) | -0.49 ± 3.333 | -0.68 ± 2.035 | 0.84 ± 1.914 | 1.04 ± 3.059 | 1.67 ± 3.059 |
| Baseline (Estradiol) | 57.33 ± 43.236 | 59.49 ± 40.129 | 35.02 ± 25.556 | 43.83 ± 31.270 | 62.42 ± 42.589 |
| Day 15 Change from Baseline (Estradiol) | 22.43 ± 141.618 | 13.21 ± 80.704 | 0.53 ± 3.172 | 1.96 ± 12.394 | -9.02 ± 87.480 |
Blood samples for the assessment of Follicle Stimulating were collected upon participants admission to the unit.
| IU/L | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 76.01 ± 23.122 | 100.87 ± 36.813 | 77.78 ± 20.132 | 88.77 ± 42.251 | 70.59 ± 17.046 |
| Day 15 Change from Baseline | 5.98 ± 13.072 | -2.29 ± 20.948 | 4.09 ± 8.353 | 6.73 ± 6.904 | 8.92 ± 13.409 |
Blood samples for the assessment of Triiodothyronine were collected upon participants admission to the unit.
| Percentage of T Uptake | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 32.300 ± 3.5623 | 30.800 ± 2.4712 | 30.838 ± 1.7968 | 30.671 ± 1.3060 | — |
| Day 15 Change from Baseline | -0.720 ± 0.7662 | -0.700 ± 0.2944 | 0.143 ± 0.7115 | 0.443 ± 1.0130 | — |
Blood samples for the assessment of Thyrotropin were collected upon participants admission to the unit.
| mIU/L | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 2.658 ± 1.7584 | 1.800 ± 0.9830 | 2.451 ± 1.4811 | 2.785 ± 1.1449 | 2.330 ± 1.2658 |
| Day 15 Change from Baseline | -0.959 ± 1.3501 | -0.571 ± 0.8148 | -0.648 ± 0.5903 | -0.823 ± 1.0604 | -0.616 ± 1.1375 |
Blood samples for the assessment of Cortisol, Testosterone, Thyroxine and Triiodothyronine were collected upon participants admission to the unit.
| nmol/L | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline (Cortisol) | 348.60 ± 156.496 | 337.16 ± 177.507 | 345.91 ± 173.302 | 251.66 ± 144.743 | 230.42 ± 74.560 |
| Day 15 Change from Baseline (Cortisol) | 15.94 ± 193.564 | -23.32 ± 172.685 | 68.05 ± 170.121 | 92.02 ± 159.464 | 127.20 ± 208.452 |
| Baseline (Testosterone) | 0.744 ± 0.3850 | 0.666 ± 0.6230 | 0.517 ± 0.2317 | 0.433 ± 0.2961 | 0.611 ± 0.4271 |
| Day 15 Change from Baseline (Testosterone) | 0.057 ± 0.3567 | 0.024 ± 0.2578 | 0.696 ± 0.3367 | 0.480 ± 0.4589 | 0.524 ± 0.2905 |
| Baseline(Thyroxine) | 95.44 ± 14.576 | 95.66 ± 15.203 | 96.11 ± 14.645 | 86.41 ± 16.116 | 94.16 ± 22.180 |
| Day 15 Change from Baseline(Thyroxine) | -3.78 ± 14.771 | -1.28 ± 8.127 | -10.67 ± 26.324 | 6.53 ± 9.546 | 0.88 ± 13.720 |
| Baseline(Triiodothyronine) | 1.865 ± 0.14131 | 2.060 ± 0.3174 | 1.980 ± 0.2916 | 1.776 ± 0.4510 | 2.163 ± 0.6008 |
| Day 15 Change from Baseline (Triiodothyronine) | -0.190 ± 0.3171 | -0.141 ± 0.2742 | -0.407 ± 0.2180 | -0.148 ± 0.1883 | -0.416 ± 0.5359 |
Blood samples for the assessment of Cholesterol, Triglycerides,high-density lipoprotein (HDL)Cholesterol and low-density lipoprotein (LDL) Cholesterol were collected upon participants admission to the unit.
| mmol/L | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline (Cholesterol) | 5.434 ± 1.0223 | 5.471 ± 0.6592 | 5.391 ± 0.7346 | 5.804 ± 0.6462 | 5.393 ± 0.9008 |
| Day 14 Change from Baseline (Cholesterol) | 0.088 ± 0.8629 | -0.061 ± 0.4761 | -0.205 ± 0.8981 | -0.185 ± 0.6386 | -0.321 ± 0.6790 |
| Baseline (Triglycerides) | 1.163 ± 0.5796 | 1.185 ± 0.5036 | 1.131 ± 0.5889 | 1.329 ± 0.6245 | 1.353 ± 0.5540 |
| Day 14 Change from Baseline (Triglycerides) | 0.048 ± 0.4936 | -0.071 ± 0.4725 | -0.116 ± 0.5247 | -0.029 ± 0.4178 | -0.172 ± 0.5633 |
| Baseline(HDL Cholesterol) | 1.717 ± 0.4525 | 1.879 ± 0.4052 | 1.7444 ± 0.6563 | 1.768 ± 0.4716 | 1.449 ± 0.2752 |
| Day 14 Change from Baseline( HDL Cholesterol) | -0.167 ± 0.2824 | -0.219 ± 0.2015 | -0.056 ± 0.2559 | -0.147 ± 0.1546 | -0.158 ± 0.3132 |
| Baseline( LDL Cholesterol) | 3.226 ± 1.0485 | 3.125 ± 0.8436 | 3.172 ± 0.7654 | 3.625 ± 0.7188 | 3.552 ± 1.1088 |
| Day 14 Change from Baseline ( LDL Cholesterol) | -0.013 ± 0.3926 | 0.184 ± 0.2958 | -0.119 ± 0.6747 | -0.038 ± 0.6490 | -0.053 ± 0.5944 |
Blood samples for the assessment of Neutrophils/Leukocytes, Lymphocytes /Leukocytes, Monocytes/Leukocytes, Eosinophils/Leukocytes, Basophils/Leukocytes and Immature Granulocytes/ Leukocytes were collected upon participants admission to the unit.
| Percentage of total white blood cells | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline (Neutrophils/ Leukocytes) | 56.53 ± 7.700 | 53.31 ± 4.994 | 55.65 ± 8.318 | 54.78 ± 8.610 | 50.92 ± 10.316 |
| Day 14 Change from Baseline (Neutrophils/ Leukocytes) | -0.29 ± 7.788 | 2.41 ± 6.119 | -0.50 ± 5.047 | -0.98 ± 7.116 | -2.69 ± 10.614 |
| Baseline (Lymphocytes/ Leukocytes) | 32.40 ± 7.098 | 35.57 ± 5.439 | 33.33 ± 8.024 | 34.33 ± 7.444 | 36.78 ± 10.446 |
| Day 14 Change from Baseline(Lymphocytes / Leukocytes) | 0.18 ± 5.791 | -2.46 ± 5.667 | -0.11 ± 4.763 | 0.59 ± 5.835 | 2.75 ± 10.926 |
| Baseline ( Monocytes / Leukocytes ) | 7.58 ± 1.592 | 7.47 ± 1.379 | 7.62 ± 1.591 | 7.71 ± 1.762 | 8.62 ± 3.276 |
| Day 14 Change from Baseline( Monocytes/ Leukocytes) | 0.22 ± 1.947 | -0.15 ± 1.751 | 0.65 ± 1.291 | 0.05 ± 2.758 | 0.22 ± 3.850 |
| Baseline ( Eosinophils/ Leukocytes) | 2.83 ± 2.433 | 3.04 ± 3.352 | 2.64 ± 1.422 | 2.61 ± 1.170 | 3.05 ± 1.979 |
| Day 14 Change from Baseline(Eosinophils/ Leukocytes) | 0.02 ± 1.316 | 0.29 ± 0.961 | 0.06 ± 0.794 | 0.33 ± 0.538 | -0.24 ± 1.189 |
| Baseline(Basophils/ Leukocytes) | 0.61 ± 0.263 | 0.55 ± 0.177 | 0.66 ± 0.295 | 0.51 ± 0.223 | 0.56 ± 0.373 |
| Day 14 Change from Baseline (Basophils/ Leukocytes) | -0.13 ± 0.181 | -0.07 ± 0.111 | -0.14 ± 0.122 | 0.01 ± 0.209 | -0.05 ± 0.307 |
| Baseline( Immature Granulocytes/ Leukocytes) | 0.15 ± 0.084 | 0.25 ± 0.100 | 0.20 ± 0.151 | 0.13 ± 0.111 | 0.15 ± 0.084 |
| Day 14 Change from Baseline( Immature Granulocytes/ Leukocytes) | 0.03 ± 0.082 | -0.05 ± 0.100 | 0.09 ± 0.157 | 0.00 ± 0.183 | 0.03 ± 0.137 |
Blood samples for the assessment of Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Immature Granulocytes and Platelets were collected upon participant's admission to the unit.
| 10^9*cells/L | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline( Leukocytes) | 6.73 ± 1.372 | 6.54 ± 1.613 | 6.75 ± 1.245 | 6.78 ± 1.307 | 6.60 ± 1.896 |
| Day 14 Change from Baseline( Leukocytes) | -0.60 ± 1.299 | -0.27 ± 1.134 | -0.34 ± 0.686 | -0.80 ± 1.011 | -0.06 ± 1.650 |
| Baseline (Neutrophils) | 3.847 ± 1.0899 | 3.493 ± 0.9737 | 3.779 ± 0.9332 | 3.745 ± 0.9686 | 3.394 ± 1.3264 |
| Day 14 Change from Baseline (Neutrophils ) | -0.374 ± 1.1794 | 0.072 ± 0.7422 | -0.246 ± 0.5487 | -0.539 ± 0.9017 | -0.186 ± 1.4444 |
| Baseline (Lymphocytes) | 2.148 ± 0.4905 | 2.341 ± 0.7009 | 2.242 ± 0.6199 | 2.320 ± 0.6467 | 2.429 ± 0.9032 |
| Day 14 Change from Baseline (Lymphocytes) | -0.172 ± 0.2900 | -0.301 ± 0.5336 | -0.107 ± 0.3652 | -0.237 ± 0.3901 | 0.142 ± 0.6749 |
| Baseline ( Monocytes) | 0.499 ± 0.0984 | 0.479 ± 0.1051 | 0.505 ± 0.0990 | 0.524 ± 0.1410 | 0.534 ± 0.1552 |
| Day 14 Change from Baseline( Monocytes) | -0.033 ± 0.1117 | -0.030 ± 0.1324 | 0.019 ± 0.0895 | -0.057 ± 0.1941 | 0.002 ± 0.1643 |
| Baseline ( Eosinophils) | 0.202 ± 0.2325 | 0.185 ± 0.1814 | 0.177 ± 0.1090 | 0.177 ± 0.0954 | 0.208 ± 0.1592 |
| Day 14 Change from Baseline(Eosinophils) | -0.017 ± 0.0995 | 0.021 ± 0.0719 | -0.006 ± 0.0549 | 0.005 ± 0.0436 | -0.028 ± 0.1155 |
| Baseline(Basophils) | 0.041 ± 0.0305 | 0.031 ± 0.0264 | 0.028 ± 0.0321 | 0.027 ± 0.0301 | 0.030 ± 0.327 |
| Day 14 Change from Baseline(Basophils) | -0.008 ± 0.0148 | -0.007 ± 0.0090 | -0.001 ± 0.0305 | -0.010 ± 0.0259 | -0.002 ± 0.0060 |
| Baseline( Immature Granulocytes) | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Day 14 Change from Baseline( Immature Granulocytes) | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Baseline (Platelets ) | 263.4 ± 59.66 | 249.1 ± 61.67 | 269.8 ± 61.40 | 261.9 ± 46.91 | 258.2 ± 52.57 |
| Day 14 Change from Baseline(Platelets ) | 8.1 ± 17.77 | 4.5 ± 33.83 | 13.5 ± 29.67 | 21.6 ± 24.58 | 20.8 ± 74.35 |
Blood samples for the assessment of Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HB)concentration were collected upon participants admission to the unit.
| g/L | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline (Hemoglobin) | 128.9 ± 8.53 | 132.4 ± 10.64 | 128.7 ± 7.82 | 127.7 ± 8.60 | 132.2 ± 12.60 |
| Day 14 Change from Baseline (Hemoglobin) | -11.8 ± 4.99 | -9.0 ± 7.14 | -14.6 ± 5.98 | -13.9 ± 4.66 | -12.1 ± 6.58 |
| Baseline (Erythrocytes Mean Corpuscular HB concentration ) | 328.5 ± 10.30 | 335.2 ± 9.42 | 329.0 ± 10.22 | 328.2 ± 7.51 | 326.8 ± 10.27 |
| Day 14 Change from Baseline (Erythrocytes Mean Corpuscular HB concentration) | -0.4 ± 5.21 | -2.5 ± 2.34 | -2.3 ± 6.94 | -0.8 ± 3.41 | 3.2 ± 4.62 |
Blood samples for the assessment of Erythrocytes were collected upon participants admission to the unit.
| 10^12*cells/L | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 4.467 ± 0.2503 | 4.525 ± 0.2212 | 4.459 ± 0.2962 | 4.365 ± 0.3678 | 4.518 ± 0.2368 |
| Day 14 Change from Baseline | -0.421 ± 0.1750 | -0.301 ± 0.2694 | -0.511 ± 0.2111 | -0.485 ± 0.1903 | -0.425 ± 0.2297 |
Blood samples for the assessment of Erythrocytes Mean Corpuscular Volume and Mean Platelet Volume were collected upon participants admission to the unit.
| fL | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline (Erythrocytes Mean Corpuscular Volume ) | 87.87 ± 5.707 | 87.69 ± 3.890 | 87.71 ± 4.717 | 89.42 ± 6.744 | 88.63 ± 3.150 |
| Day 14 Change from Baseline (Erythrocytes Mean Corpuscular Volume ) | 0.44 ± 1.155 | 0.11 ± 0.799 | 0.47 ± 0.967 | 0.49 ± 1,691 | -0.27 ± 0.659 |
| Baseline (Mean Platelet Volume) | 9.79 ± 0.809 | 9.91 ± 1.608 | 10.22 ± 1.565 | 10.19 ± 1.005 | 10.05 ± 1.179 |
| Day 14 Change from Baseline (Mean Platelet Volume) | -0.14 ± 0.448 | 0.08 ± 0.412 | -0.24 ± 0.220 | -0.37 ± 0.403 | -0.06 ± 0.216 |
Blood samples for the assessment of Erythrocytes Mean Corpuscular Hemoglobin were collected upon participants admission to the unit.
| pg | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 28.89 ± 2.517 | 29.50 ± 1.803 | 28.79 ± 2.217 | 29.39 ± 2.511 | 28.89 ± 1.759 |
| Day 14 Change from Baseline | 0.09 ± 0.494 | -0.19 ± 0.263 | 0.03 ± 0.486 | 0.15 ± 0.532 | 0.17 ± 0.317 |
Blood samples for the assessment of Erythrocytes Distribution Width were collected upon participants admission to the unit. Erythrocytes distribution width (in percentage) = 1 SD of Erythrocyte volume/MCV x 100%
| Percentage of Erythrocyte volume | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 27.81 ± 15.478 | 25.52 ± 15.413 | 35.82 ± 16.476 | 30.59 ± 16.089 | 31.48 ± 17.013 |
| Day 14 Change from Baseline | -0.15 ± 0.916 | 0.49 ± 0.863 | -0.05 ± 1.878 | -0.61 ± 0.696 | -0.68 ± 0.778 |
Blood samples for the assessment of Hematocrit were collected upon participants admission to the unit.
| Volume percentage | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 39.18 ± 1.976 | 39.63 ± 2.461 | 38.99 ± 1.788 | 38.85 ± 1.990 | 40.02 ± 2.646 |
| Day 14 Change from Baseline | -3.51 ± 1.307 | -2.45 ± 2.106 | -4.20 ± 1.877 | -4.13 ± 1.431 | -3.86 ± 2.163 |
Blood samples for the assessment of Protein and Albumin were collected upon participants admission to the unit.
| g/L | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline (Protein) | 71.8 ± 4.54 | 72.2 ± 4.13 | 74.3 ± 4.25 | 70.5 ± 4.84 | 69.2 ± 4.22 |
| Day 14 Change from Baseline(Protein) | -4.0 ± 3.11 | -2.5 ± 4.39 | -6.9 ± 4.89 | -4.1 ± 2.64 | -2.5 ± 3.10 |
| Baseline(Albumin) | 42.9 ± 6.75 | 44.3 ± 1.84 | 44.4 ± 2.53 | 44.7 ± 2.53 | 43.2 ± 2.67 |
| Day 14 Change from Baseline (Albumin) | -0.6 ± 6.42 | -2.5 ± 2.42 | -3.2 ± 2.08 | 0.3 ± 2.05 | -1.8 ± 2.44 |
Blood samples for the assessment of Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Creatine Kinase were collected upon participants admission to the unit.
| ukat/L | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline (Alkaline Phosphatase) | 1.587 ± 0.4829 | 1.397 ± 0.3233 | 1.364 ± 0.3219 | 1.397 ± 0.3271 | 1.407 ± 0.4417 |
| Day 14 Change from Baseline (Alkaline Phosphatase) | -0.129 ± 0.3411 | -0.130 ± 0.2054 | -0.172 ± 0.1533 | -0.203 ± 0.2576 | -0.131 ± 0.2958 |
| Baseline(Alanine Aminotransferase) | 0.295 ± 0.1302 | 0.331 ± 0.1494 | 0.279 ± 0.1151 | 0.313 ± 0.1281 | 0.413 ± 0.1755 |
| Day 14 Change from Baseline (Alanine Aminotransferase) | 0.108 ± 0.4103 | -0.049 ± 0.1053 | 0.049 ± 0,2099 | -0.016 ± 0.1391 | 0.052 ± 0.3923 |
| Baseline (Aspartate Aminotransferase) | 0.344 ± 0.0760 | 0.355 ± 0.0632 | 0.343 ± 0.0950 | 0.352 ± 0.0737 | 0.401 ± 0.1976 |
| Day 14 Change from Baseline (Aspartate Aminotransferase) | 0.041 ± 0.2197 | -0.035 ± 0.0542 | -0.032 ± 0.1030 | -0.009 ± 0.0743 | -0.032 ± 0.2851 |
| Baseline (Gamma Glutamyl Transferase) | 0.309 ± 0.1740 | 0.324 ± 0.2085 | 0.397 ± 0.2111 | 0.561 ± 0.7998 | 0.372 ± 0.2272 |
| Day 14 Change from Baseline (Gamma Glutamyl Transferase) | 0.101 ± 0.3890 | -0.035 ± 0.0980 | 0.001 ± 0.1606 | -0.190 ± 0.4620 | 0.015 ± 0.1959 |
| Baseline (Creatine Kinase) | 1.957 ± 0.8872 | 2.047 ± 1.0146 | 1.907 ± 1.1933 | 1.895 ± 1.2638 | 1.886 ± 1.1854 |
| Day 14 Change from Baseline (Creatine Kinase) | 0.021 ± 0.9758 | -0.260 ± 0.4338 | -0.252 ± 0.5078 | -0.038 ± 0.5689 | -0.269 ± 0.5032 |
Blood samples for the assessment of Urate, Bilirubin and Creatinine were collected upon participants admission to the unit.
| umol/L | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline (Urate) | 297.43 ± 41.896 | 318.23 ± 20.323 | 261.74 ± 57.222 | 275.34 ± 75.528 | 212.17 ± 52.885 |
| Day 14 Change from Baseline (Urate) | -11.90 ± 41.380 | -2.95 ± 28.511 | 2.57 ± 19.706 | -12.76 ± 28.636 | -7.93 ± 44.269 |
| Baseline (Bilirubin) | 7.61 ± 3.500 | 8.44 ± 3.640 | 7.19 ± 2.932 | 6.96 ± 2.652 | 7.23 ± 3.305 |
| Day 14 Change from Baseline(Bilirubin) | -1.25 ± 3.225 | -1.15 ± 2.654 | -1.00 ± 1.886 | -0.01 ± 2.599 | 0.40 ± 3.069 |
| Baseline(Creatinine) | 71.162 ± 11.3215 | 67.125 ± 8.0711 | 65.121 ± 9.8867 | 67.891 ± 9.1636 | 11.844 ± 8.9096 |
| Day 14 Change from Baseline(Creatinine) | 2.652 ± 6.4810 | -1.885 ± 7.8090 | -4.168 ± 7.6761 | -1.297 ± 6.6136 | -3.605 ± 5.6665 |
Blood samples for the assessment of Sodium, Potassium, Chloride, Bicarbonate, Calcium, Phosphate, Glucose, Magnesium and Urea Nitrogen were collected upon participant's admission to the unit.
| mmol/L | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline (Sodium) | 140.7 ± 2.93 | 140.3 ± 2.05 | 140.0 ± 1.65 | 142.3 ± 3.01 | 140.0 ± 2.83 |
| Day 14 Change from Baseline (Sodium) | -0.9 ± 2.91 | -0.7 ± 2.97 | -0.5 ± 2.28 | -2.5 ± 3.23 | 0.7 ± 3.47 |
| Baseline (Potassium) | 4.41 ± 0.375 | 4.22 ± 0.246 | 4.29 ± 0.374 | 4.49 ± 0.380 | 4.14 ± 0.421 |
| Day 14 Change from Baseline (Potassium) | 0.06 ± 0.478 | 0.22 ± 0.323 | 0.15 ± 0.427 | -0.06 ± 0.408 | 0.31 ± 0.614 |
| Baseline (Chloride) | 102.8 ± 2.94 | 102.4 ± 3.79 | 100.7 ± 2.32 | 102.7 ± 2.84 | 101.4 ± 1.56 |
| Day 14 Change from Baseline ( Chloride) | -1.2 ± 3.20 | 0.4 ± 3.16 | 1.1 ± 1.69 | -1.1 ± 3.02 | 0.8 ± 2.88 |
| Baseline (Bicarbonate) | 26.39 ± 2.615 | 26.60 ± 2.131 | 27.47 ± 1.642 | 26.20 ± 1.699 | 27.62 ± 3.641 |
| Day 14 Change from Baseline (Bicarbonate) | 1.11 ± 3.660 | -0.93 ± 3.575 | 1.00 ± 3.088 | 2.00 ± 2.204 | 0.31 ± 2.626 |
| Baseline (Calcium) | 2.421 ± 0.0803 | 2.401 ± 0.0730 | 2.515 ± 0.0998 | 2.411 ± 0.0622 | 2.382 ± 0.0928 |
| Day 14 Change from Baseline (Calcium) | -0.032 ± 0.1198 | -0.044 ± 0.1355 | -0.144 ± 0.1147 | -0.049 ± 0.0630 | -0.052 ± 0.1103 |
| Baseline (Phosphate) | 1.240 ± 0.1510 | 1.249 ± 0.1277 | 1.268 ± 0.1269 | 1.280 ± 0.1115 | 1.272 ± 0.1544 |
| Day 14 Change from Baseline (Phosphate) | 0.026 ± 0.1602 | -0.045 ± 0.1457 | -0.052 ± 0.1096 | 0.027 ± 0.1389 | -0.038 ± 0.2171 |
| Baseline (Glucose) | 5.457 ± 0.6417 | 5.521 ± 0.4157 | 5.349 ± 0.4957 | 5.483 ± 0.3943 | 5.456 ± 0.4401 |
| Day 14 Change from Baseline (Glucose) | -0.113 ± 0.9083 | -0.278 ± 0.4006 | -0.173 ± 0.3412 | -0.098 ± 0.4245 | 0.025 ± 0.3063 |
| Baseline (Magnesium) | 0.893 ± 0.0732 | 0.885 ± 0.0588 | 0.881 ± 0.0675 | 0.905 ± 0.0703 | 0.896 ± 0.0836 |
| Day 14 Change from Baseline (Magnesium) | -0.009 ± 0.0460 | 0.001 ± 0.0387 | 0.001 ± 0.0529 | 0.006 ± 0.0484 | -0.027 ± 0.0696 |
| Baseline (Urea Nitrogen) | 5.59 ± 1.230 | 5.47 ± 1.337 | 4.67 ± 1.274 | 5.30 ± 1.198 | 5.21 ± 1.393 |
| Day 14 Change from Baseline (Urea Nitrogen) | 0.14 ± 2.359 | -0.14 ± 1.070 | 0.20 ± 0.826 | 0.00 ± 1.442 | -0.38 ± 1.488 |
Blood samples for the assessment of Glomerular Filtration Rate African were collected upon participants admission to the unit.
| mL/sec/1.73m^2 | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate African at Baseline | 1.628 ± 0.2347 | 1.759 ± 0.1592 | 1.580 ± 0.1846 | 1.557 ± 0.1553 | 1.666 ± 0.1885 |
Blood samples for the assessment of Glomerular Filtration Rate Caucasian were collected upon participants admission to the unit.
| mL/sec/1.73m^2 | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate Caucasian at Baseline | 1.343 ± 0.1955 | 1.450 ± 0.1265 | 1.300 ± 0.1503 | 1.290 ± 0.1273 | 1.378 ± 0.1482 |
Blood samples for the assessment of Prothrombin International Normalized Ratio were collected upon participants admission to the unit.
| INR | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline | 0.993 ± 0.0428 | 1.013 ± 0.0552 | 1.007 ± 0.0482 | 0.991 ± 0.0465 | 0.993 ± 0.0645 |
| Day 14 Change from Baseline | -0.007 ± 0.0546 | -0.038 ± 0.0471 | 0.016 ± 0.0665 | 0.013 ± 0.0359 | 0.057 ± 0.2311 |
Blood samples for the assessment of Prothrombin Time and Activated Partial Thromboplastin Time were collected upon participants admission to the unit.
| sec | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline (Prothrombin Time ) | 11.17 ± 1.871 | 11.05 ± 1.679 | 11.91 ± 1.871 | 11.51 ± 1.757 | 11.47 ± 1.589 |
| Day 14 Change from Baseline (Prothrombin Time) | -0.15 ± 0.507 | -0.32 ± 0.351 | 0.12 ± 0.503 | 0.11 ± 0.291 | 0.55 ± 2.363 |
| Baseline(Activated Partial Thromboplastin Time) | 26.91 ± 2.435 | 27.09 ± 2.495 | 28.14 ± 2.483 | 27.50 ± 2.872 | 27.55 ± 3.009 |
| Day 14 Change from Baseline (Activated Partial Thromboplastin Time) | -0.82 ± 1.350 | -1.80 ± 1.489 | -0.81 ± 1.478 | -0.87 ± 1.396 | 0.58 ± 3.196 |
Heart rate was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made.Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.
| beats/min | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Day -1(Predose) | 65.7 ± 9.50 | 61.6 ± 6.43 | 65.3 ± 8.43 | 64.5 ± 5.85 | 65.0 ± 7.16 |
| Day -1 (0.5 hour) | 68.5 ± 9.54 | 64.5 ± 8.76 | 66.7 ± 10.56 | 66.1 ± 9.13 | 68.7 ± 9.94 |
| Day -1 (1 hour) | 69.8 ± 9.27 | 66.8 ± 9.58 | 66.2 ± 9.31 | 67.6 ± 5.69 | 67.2 ± 7.77 |
| Day -1 (1.5 hour) | 68.9 ± 9.26 | 67.3 ± 7.24 | 66.5 ± 9.09 | 67.3 ± 5.38 | 67.5 ± 7.37 |
| Day -1 (2 hour) | 70.2 ± 10.95 | 67.3 ± 7.81 | 65.9 ± 9.96 | 65.2 ± 4.38 | 66.3 ± 8.36 |
| Day -1 (2.5 hour) | 68.7 ± 9.02 | 69.4 ± 8.86 | 64.6 ± 10.11 | 65.1 ± 4.19 | 68.2 ± 10.32 |
| Day -1 (3 hour) | 69.4 ± 9.06 | 64.3 ± 4.91 | 65.6 ± 7.89 | 67.9 ± 5.79 | 68.8 ± 7.51 |
| Day -1 (4 hour) | 68.0 ± 10.50 | 62.8 ± 6.70 | 64.3 ± 6.20 | 63.9 ± 5.54 | 67.5 ± 8.40 |
| Day -1 (8 hour) | 72.9 ± 10.38 | 64.4 ± 5.95 | 70.2 ± 10.68 | 66.9 ± 7.17 | 70.2 ± 8.14 |
| Day -1 (12 hour) | 77.0 ± 9.63 | 68.7 ± 8.96 | 73.6 ± 7.43 | 70.7 ± 7.81 | 71.6 ± 8.69 |
| Day 14 (Pre dose) Change from Baseline | -0.4 ± 6.87 | -0.3 ± 4.08 | 0.8 ± 6.14 | -2.1 ± 6.96 | -3.8 ± 8.85 |
| Day 14 (0.5 hour) Change from Baseline | -2.6 ± 7.58 | -5.1 ± 8.48 | -0.9 ± 10.10 | -4.3 ± 10.24 | -9.6 ± 10.13 |
| Day 14 (1 hour) Change from Baseline | -5.0 ± 8.66 | -6.7 ± 9.65 | -0.6 ± 9.18 | -7.9 ± 8.35 | -7.7 ± 6.92 |
| Day 14 (1.5 hour) Change from Baseline | -5.5 ± 8.13 | -7.4 ± 7.24 | -1.5 ± 7.10 | -7.9 ± 8.07 | -7.6 ± 8.08 |
| Day 14 (2 hour) Change from Baseline | -6.5 ± 10.98 | -7.9 ± 7.98 | -2.4 ± 8.54 | -4.2 ± 7.90 | -7.0 ± 6.94 |
| Day 14 (2.5 hour) Change from Baseline | -4.2 ± 7.16 | -10.5 ± 8.60 | -0.3 ± 7.05 | -4.2 ± 4.95 | -7.8 ± 10.48 |
| Day 14 (3 hour) Change from Baseline | -4.9 ± 9.94 | -4.6 ± 5.05 | -0.4 ± 8.45 | -7.5 ± 7.74 | -5.7 ± 9.94 |
| Day 14 (4 hour) Change from Baseline | -4.3 ± 8.57 | -2.9 ± 4.83 | 0.2 ± 8.86 | -2.0 ± 7.36 | -5.8 ± 7.62 |
| Day 14 (8 hour) Change from Baseline | -2.2 ± 6.22 | 0.5 ± 5.15 | 6.8 ± 8.99 | 1.0 ± 6.47 | -2.3 ± 9.40 |
| Day 14 (12 hour) Change from Baseline | -0.9 ± 5.70 | 0.7 ± 5.74 | 2.3 ± 8.26 | 0.0 ± 5.49 | -3.2 ± 9.57 |
PR Interval was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.
| msec | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Day -1 (Predose) | 165.3 ± 22.20 | 152.6 ± 14.30 | 165.3 ± 26.10 | 166.6 ± 26.74 | 162.6 ± 20.52 |
| Day -1 (0.5 hour) | 163.3 ± 24.69 | 155.3 ± 20.19 | 167.1 ± 26.74 | 162.1 ± 22.13 | 162.4 ± 20.59 |
| Day -1 (1 hour) | 166.3 ± 23.76 | 155.7 ± 20.43 | 166.6 ± 25.79 | 166.5 ± 24.32 | 162.1 ± 19.82 |
| Day -1 (1.5 hour) | 167.6 ± 22.91 | 158.9 ± 17.73 | 165.9 ± 21.47 | 164.9 ± 26.07 | 162.4 ± 17.60 |
| Day -1 (2 hour) | 166.9 ± 25.01 | 156.0 ± 18.95 | 167.1 ± 22.27 | 164.9 ± 25.23 | 162.9 ± 21.16 |
| Day -1 (2.5 hour) | 168.7 ± 26.32 | 155.3 ± 18.32 | 165.8 ± 26.24 | 165.2 ± 26.51 | 160.4 ± 21.99 |
| Day -1 (3 hour) | 168.0 ± 25.66 | 153.7 ± 17.61 | 170.1 ± 31.39 | 161.8 ± 23.66 | 160.1 ± 20.10 |
| Day -1 (4 hour) | 165.6 ± 24.06 | 155.4 ± 17.27 | 165.1 ± 20.73 | 163.6 ± 26.48 | 161.6 ± 16.78 |
| Day -1 (8 hour) | 162.1 ± 23.67 | 152.5 ± 17.45 | 161.7 ± 22.93 | 163.5 ± 25.00 | 156.4 ± 16.60 |
| Day -1 (12 hour) | 165.7 ± 26.90 | 157.7 ± 17.41 | 158.5 ± 19.56 | 159.0 ± 21.78 | 156.5 ± 17.71 |
| Day 14 (Pre dose) Change from Baseline | 5.6 ± 12.32 | 1.7 ± 6.41 | -1.8 ± 10.85 | -0.3 ± 9.42 | 0.9 ± 12.78 |
| Day 14 (0.5 hour) Change from Baseline | 8.5 ± 20.00 | 0.4 ± 6.90 | 0.9 ± 14.64 | 4.6 ± 12.49 | -0.8 ± 13.90 |
| Day 14 (1 hour) Change from Baseline | 5.6 ± 15.88 | 2.8 ± 9.03 | -1.0 ± 14.15 | 2.7 ± 19.24 | 1.7 ± 13.74 |
| Day 14 (1.5 hour) Change from Baseline | -1.0 ± 12.86 | -2.8 ± 9.59 | 3.9 ± 17.63 | -0.5 ± 11.47 | 1.8 ± 17.08 |
| Day 14 (2 hour) Change from Baseline | 4.1 ± 12.56 | 0.6 ± 8.85 | -0.9 ± 17.72 | 0.9 ± 11.82 | 4.2 ± 14.32 |
| Day 14 (2.5 hour) Change from Baseline | 2.2 ± 9.34 | 2.6 ± 13.33 | 0.0 ± 11.96 | 1.8 ± 12.11 | 8.3 ± 15.96 |
| Day 14 (3 hour) Change from Baseline | 3.8 ± 11.09 | 5.3 ± 11.40 | -3.1 ± 10.83 | 4.5 ± 15.01 | 4.9 ± 14.78 |
| Day 14 (4 hour) Change from Baseline | 5.7 ± 15.13 | 1.4 ± 6.48 | 5.2 ± 20.77 | 1.8 ± 14.49 | 2.2 ± 9.05 |
| Day 14 (8 hour) Change from Baseline | 1.4 ± 8.66 | 2.9 ± 5.95 | 0.1 ± 15.03 | -3.9 ± 12.21 | 5.2 ± 6.54 |
| Day 14 (12 hour) Change from Baseline | -0.4 ± 8.83 | -3.6 ± 9.17 | -0.1 ± 11.07 | 2.0 ± 9.33 | 0.9 ± 10.80 |
QRS Duration was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.
| msec | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Day -1(Predose) | 88.8 ± 10.82 | 93.6 ± 8.11 | 84.7 ± 6.39 | 89.2 ± 10.99 | 89.5 ± 11.76 |
| Day -1 (0.5 hour | 88.7 ± 10.44 | 94.5 ± 7.94 | 87.4 ± 8.44 | 88.5 ± 10.86 | 88.9 ± 10.73 |
| Day -1 (1 hour) | 88.7 ± 10.22 | 93.3 ± 7.17 | 85.2 ± 7.94 | 90.3 ± 9.91 | 91.2 ± 13.04 |
| Day -1 (1.5 hour) | 89.4 ± 11.77 | 91.7 ± 8.52 | 85.0 ± 7.98 | 89.5 ± 10.20 | 92.2 ± 11.59 |
| Day -1 (2 hour) | 86.4 ± 11.08 | 90.5 ± 7.98 | 84.0 ± 5.83 | 89.5 ± 11.15 | 89.0 ± 10.04 |
| Day -1 (2.5 hour) | 87.6 ± 12.27 | 91.5 ± 8.94 | 84.4 ± 8.22 | 89.0 ± 10.27 | 87.8 ± 10.80 |
| Day -1 (3 hour) | 86.4 ± 10.10 | 92.7 ± 6.94 | 85.7 ± 9.32 | 88.6 ± 10.10 | 87.9 ± 11.06 |
| Day -1 (4 hour) | 86.2 ± 11.68 | 92.3 ± 8.26 | 85.1 ± 9.68 | 87.7 ± 11.04 | 88.7 ± 11.53 |
| Day -1 (8 hour) | 85.4 ± 11.26 | 90.9 ± 9.16 | 81.1 ± 4.41 | 85.4 ± 11.79 | 85.3 ± 11.46 |
| Day -1 (12 hour) | 86.6 ± 10.53 | 92.0 ± 7.93 | 85.5 ± 9.13 | 86.3 ± 10.55 | 88.1 ± 13.08 |
| Day 14 (Pre dose) Change from Baseline | -0.7 ± 3.63 | 0.3 ± 3.89 | -0.8 ± 4.56 | -0.1 ± 6.71 | 3.1 ± 7.80 |
| Day 14 (0.5 hour) Change from Baseline | 1.0 ± 7.64 | -1.2 ± 5.87 | -3.1 ± 5.37 | 0.4 ± 6.53 | 2.8 ± 5.06 |
| Day 14 (1 hour) Change from Baseline | 0.7 ± 6.66 | 0.0 ± 3.57 | -1.6 ± 7.46 | -0.1 ± 8.88 | -2.5 ± 10.73 |
| Day 14 (1.5 hour) Change from Baseline | -0.8 ± 6.00 | 1.5 ± 6.83 | -2.0 ± 6.26 | 3.4 ± 6.74 | -1.8 ± 8.62 |
| Day 14 (2 hour) Change from Baseline | 1.7 ± 8.08 | 3.2 ± 5.87 | -0.8 ± 5.25 | 1.9 ± 8.34 | 1.0 ± 8.08 |
| Day 14 (2.5 hour) Change from Baseline | 1.7 ± 7.13 | 0.9 ± 4.96 | 0.4 ± 7.02 | 1.2 ± 5.61 | 3.4 ± 7.39 |
| Day 14 (3 hour) Change from Baseline | 2.2 ± 5.41 | 0.5 ± 4.87 | -1.5 ± 6.56 | -1.5 ± 7.06 | 2.6 ± 8.90 |
| Day 14 (4 hour) Change from Baseline | 1.9 ± 6.27 | 0.5 ± 4.61 | -2.5 ± 6.44 | 14.8 ± 49.01 | 1.7 ± 7.80 |
| Day 14 (8 hour) Change from Baseline | -0.3 ± 3.82 | 1.5 ± 4.63 | 0.4 ± 3.41 | 0.9 ± 6.26 | 2.5 ± 6.05 |
| Day 14 (12 hour) Change from Baseline | -1.7 ± 6.91 | 0.3 ± 2.85 | -3.3 ± 9.28 | -0.5 ± 5.49 | -0.8 ± 7.69 |
QT Interval was measured as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.
| msec | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Day -1 (Predose) | 421.8 ± 31.07 | 426.4 ± 23.73 | 412.6 ± 29.12 | 421.8 ± 22.12 | 411.3 ± 16.01 |
| Day -1 (0.5 hour | 412.4 ± 27.58 | 422.0 ± 24.00 | 410.1 ± 29.29 | 417.7 ± 22.13 | 405.6 ± 22.19 |
| Day -1 (1 hour) | 412.6 ± 22.81 | 414.6 ± 21.41 | 415.6 ± 29.17 | 414.8 ± 21.32 | 406.5 ± 21.20 |
| Day -1 (1.5 hour) | 413.7 ± 23.60 | 408.4 ± 19.91 | 408.0 ± 23.71 | 414.9 ± 21.19 | 412.3 ± 22.31 |
| Day -1 (2 hour) | 407.4 ± 25.64 | 405.8 ± 19.18 | 410.7 ± 33.40 | 413.4 ± 20.20 | 412.7 ± 22.32 |
| Day -1 (2.5 hour) | 411.3 ± 27.10 | 403.4 ± 27.70 | 410.9 ± 32.10 | 418.9 ± 32.10 | 412.4 ± 26.30 |
| Day -1 (3 hour) | 407.8 ± 25.47 | 411.9 ± 22.80 | 409.9 ± 24.92 | 410.7 ± 23.04 | 401.2 ± 23.18 |
| Day -1 (4 hour) | 408.3 ± 32.47 | 414.9 ± 20.19 | 411.2 ± 21.83 | 418.1 ± 19.01 | 407.8 ± 16.98 |
| Day -1 (8 hour) | 398.9 ± 29.10 | 410.3 ± 19.54 | 396.3 ± 26.84 | 405.7 ± 22.57 | 398.5 ± 27.65 |
| Day -1 (12 hour) | 389.2 ± 28.40 | 407.1 ± 22.55 | 395.5 ± 22.33 | 402.2 ± 26.39 | 394.4 ± 28.85 |
| Day 14 (Pre dose) Change from Baseline | -6.8 ± 17.03 | 0.2 ± 15.11 | -9.6 ± 20.16 | -2.1 ± 24.54 | 5.5 ± 21.03 |
| Day 14 (0.5 hour) Change from Baseline | 2.3 ± 17.73 | 8.7 ± 13.13 | -2.4 ± 23.90 | 10.2 ± 25.32 | 20.8 ± 24.94 |
| Day 14 (1 hour) Change from Baseline | 6.9 ± 18.73 | 17.8 ± 15.93 | -7.9 ± 28.71 | 16.3 ± 20.43 | 17.8 ± 22.08 |
| Day 14 (1.5 hour) Change from Baseline | 11.7 ± 22.95 | 24.5 ± 14.95 | -0.5 ± 19.09 | 15.7 ± 21.82 | 17.5 ± 21.80 |
| Day 14 (2 hour) Change from Baseline | 14.2 ± 25.19 | 25.5 ± 18.13 | 3.6 ± 25.04 | 16.3 ± 20.76 | 16.2 ± 16.67 |
| Day 14 (2.5 hour) Change from Baseline | 9.5 ± 25.18 | 28.3 ± 22.66 | 1.4 ± 24.51 | 12.9 ± 21.11 | 14.0 ± 23.04 |
| Day 14 (3 hour) Change from Baseline | 14.2 ± 28.90 | 17.4 ± 15.42 | 1.9 ± 18.66 | 18.3 ± 23.65 | 17.8 ± 28.64 |
| Day 14 (4 hour) Change from Baseline | 12.6 ± 22.90 | 13.5 ± 15.04 | -2.8 ± 23.91 | 5.5 ± 23.97 | 18.3 ± 22.05 |
| Day 14 (8 hour) Change from Baseline | 2.4 ± 14.71 | -1.9 ± 12.65 | -14.2 ± 18.23 | -3.7 ± 20.76 | 6.6 ± 27.45 |
| Day 14 (12 hour) Change from Baseline | 3.0 ± 17.62 | -0.8 ± 13.58 | -12.9 ± 18.71 | -1.8 ± 16.37 | 7.8 ± 24.27 |
Fridericia-corrected QTcF interval was evaluated as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.
| msec | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Day -1(Predose) | 432.7 ± 18.75 | 429.0 ± 16.87 | 422.3 ± 14.41 | 431.1 ± 17.28 | 421.8 ± 20.02 |
| Day -1 (0.5 hour) | 429.2 ± 16.14 | 430.9 ± 18.81 | 422.3 ± 14.40 | 430.1 ± 16.21 | 422.6 ± 15.35 |
| Day -1 (1 hour) | 432.2 ± 14.68 | 428.3 ± 14.85 | 427.3 ± 16.15 | 430.9 ± 16.46 | 420.8 ± 13.55 |
| Day -1 (1.5 hour) | 431.7 ± 18.47 | 423.4 ± 17.60 | 420.6 ± 14.81 | 430.5 ± 15.73 | 427.6 ± 15.24 |
| Day -1 (2 hour) | 427.2 ± 17.33 | 420.5 ± 13.47 | 420.9 ± 15.57 | 424.5 ± 16.55 | 425.2 ± 15.08 |
| Day -1 (2.5 hour) | 428.7 ± 19.29 | 422.1 ± 21.46 | 418.3 ± 17.41 | 429.9 ± 18.39 | 428.3 ± 17.29 |
| Day -1 (3 hour) | 426.7 ± 16.64 | 420.3 ± 18.14 | 419.9 ± 15.56 | 427.0 ± 15.46 | 419.0 ± 17.83 |
| Day -1 (4 hour) | 423.4 ± 19.52 | 420.3 ± 18.14 | 419.9 ± 14.74 | 426.2 ± 13.33 | 423.2 ± 19.46 |
| Day -1 (8 hour) | 423.8 ± 16.12 | 419.3 ± 15.99 | 415.5 ± 17.53 | 419.7 ± 16.65 | 418.8 ± 25.31 |
| Day -1 (12 hour) | 421.2 ± 16.25 | 424.2 ± 13.91 | 422.1 ± 11.25 | 423.7 ± 20.16 | 416.8 ± 20.10 |
| Day 14 (Pre dose) Change from Baseline | -6.6 ± 11.74 | 0.3 ± 12.75 | -7.9 ± 13.31 | -6.6 ± 22.83 | -3.8 ± 13.46 |
| Day 14 (0.5 hour) Change from Baseline | -3.0 ± 14.97 | -2.9 ± 9.31 | -4.4 ± 10.52 | 1.1 ± 14.51 | 0.4 ± 12.92 |
| Day 14 (1 hour) Change from Baseline | -2.6 ± 11.94 | 2.7 ± 11.08 | -8.4 ± 12.88 | -1.2 ± 18.18 | 1.6 ± 15.34 |
| Day 14 (1.5 hour) Change from Baseline | 0.1 ± 13.97 | 8.3 ± 15.45 | -3.8 ± 9.02 | -2.1 ± 15.16 | 0.6 ± 15.77 |
| Day 14 (2 hour) Change from Baseline | 1.3 ± 17.40 | 8.7 ± 11.48 | -0.4 ± 15.25 | 6.7 ± 10.09 | 0.8 ± 12.58 |
| Day 14 (2.5 hour) Change from Baseline | 1.1 ± 20.94 | 5.9 ± 18.24 | 2.3 ± 13.84 | 3.8 ± 16.62 | -2.3 ± 12.11 |
| Day 14 (3 hour) Change from Baseline | 3.6 ± 13.91 | 7.0 ± 17.29 | 0.3 ± 7.71 | 2.2 ± 12.14 | 5.5 ± 15.08 |
| Day 14 (4 hour) Change from Baseline | 4.6 ± 11.77 | 7.1 ± 14.96 | -3.8 ± 11.34 | 0.1 ± 15.55 | 6.2 ± 22.76 |
| Day 14 (8 hour) Change from Baseline | -2.0 ± 9.55 | -1.1 ± 10.67 | -1.3 ± 13.74 | -1.8 ± 14.03 | 2.0 ± 22.20 |
| Day 14 (12 hour) Change from Baseline | 1.2 ± 14.43 | 1.3 ± 10.33 | -9.4 ± 13.78 | -1.3 ± 17.43 | 2.8 ± 17.21 |
Bazett-corrected QTcB interval was evaluated as part of the 12-lead electrocardiogram. Resting ECG recordings were made. Holter monitors were fitted to participants upon admission in clinic on Day -1 and Day 14.
| msec | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Day -1 (Predose) | 438.6 ± 18.07 | 430.7 ± 18.10 | 427.6 ± 13.14 | 436.1 ± 17.61 | 417.3 ± 25.91 |
| Day -1 (0.5 hour) | 438.1 ± 16.29 | 435.6 ± 21.78 | 429.1 ± 19.47 | 436.5 ± 20.61 | 431.8 ± 20.32 |
| Day -1 (1 hour) | 442.8 ± 17.55 | 435.3 ± 18.84 | 433.7 ± 18.90 | 439.4 ± 16.23 | 428.8 ± 15.65 |
| Day -1 (1.5 hour) | 441.3 ± 22.48 | 431.3 ± 20.62 | 427.4 ± 18.56 | 438.5 ± 15.28 | 436.0 ± 16.65 |
| Day -1 (2 hour) | 437.8 ± 21.87 | 428.3 ± 16.51 | 426.6 ± 17.12 | 430.3 ± 16.49 | 432.1 ± 18.48 |
| Day -1 (2.5 hour) | 438.1 ± 21.09 | 432.1 ± 22.47 | 422.7 ± 19.67 | 435.9 ± 18.04 | 436.9 ± 21.27 |
| Day -1 (3 hour) | 436.6 ± 18.42 | 425.7 ± 22.43 | 426.7 ± 16.74 | 435.5 ± 13.93 | 428.4 ± 19.40 |
| Day -1 (4 hour) | 431.6 ± 18.31 | 423.4 ± 21.21 | 424.6 ± 15.43 | 430.3 ± 14.06 | 431.2 ± 26.00 |
| Day -1 (8 hour) | 437.0 ± 14.34 | 424.2 ± 17.81 | 425.9 ± 21.39 | 427.1 ± 18.11 | 429.5 ± 27.28 |
| Day -1 (12 hour) | 438.3 ± 13.91 | 433.4 ± 16.01 | 436.4 ± 9.44 | 434.9 ± 20.98 | 428.8 ± 17.99 |
| Day 14 (Pre dose) Change from Baseline | -6.7 ± 14.73 | -0.3 ± 13.93 | -6.9 ± 14.02 | -8.9 ± 25.90 | -8.5 ± 17.83 |
| Day 14 (0.5 hour) Change from Baseline | -5.9 ± 19.59 | -8.9 ± 17.34 | -5.5 ± 13.67 | -3.4 ± 19.47 | -10.3 ± 17.32 |
| Day 14 (1 hour) Change from Baseline | -8.0 ± 16.86 | -4.6 ± 19.55 | -8.9 ± 13.33 | -10.3 ± 23.07 | -7.5 ± 16.25 |
| Day 14 (1.5 hour) Change from Baseline | -6.1 ± 16.42 | 0.0 ± 21.00 | -5.5 ± 10.36 | -11.1 ± 18.95 | -8.5 ± 19.32 |
| Day 14 (2 hour) Change from Baseline | -5.7 ± 24.18 | -0.1 ± 15.10 | -2.9 ± 19.35 | 1.9 ± 13.13 | -7.5 ± 16.37 |
| Day 14 (2.5 hour) Change from Baseline | -3.4 ± 23.12 | -5.7 ± 22.17 | 2.2 ± 15.76 | -1.4 ± 17.37 | -10.8 ± 16.97 |
| Day 14 (3 hour) Change from Baseline | -1.6 ± 13.90 | 1.9 ± 20.81 | -0.4 ± 11.01 | -6.3 ± 12.49 | -0.7 ± 14.57 |
| Day 14 (4 hour) Change from Baseline | 0.4 ± 13.21 | 3.3 ± 17.73 | -4.2 ± 12.68 | -2.2 ± 16.13 | -0.1 ± 27.06 |
| Day 14 (8 hour) Change from Baseline | -4.4 ± 12.46 | -0.8 ± 13.48 | 5.5 ± 19.09 | -0.9 ± 14.17 | -0.2 ± 24.65 |
| Day 14 (12 hour) Change from Baseline | 0.3 ± 15.11 | 2.1 ± 13.19 | -7.5 ± 16.64 | -1.2 ± 20.57 | -0.2 ± 18.66 |
An AE was defined as any untoward medical occurrence in a subject or clinical trial subject administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product. Serious Adverse Event (SAE) is an adverse event that at any dose: Results in death, Is life-threatening (i.e. the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe), Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is considered to be an important medical event.
| Participants | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Any TEAE | 13 | 7 | 11 | 10 | 11 |
| Any Mild TEAE | 12 | 7 | 10 | 10 | 11 |
| Any Moderate TEAE | 1 | 1 | 1 | 1 | 1 |
| Any Severe TEAE | 0 | 0 | 0 | 0 | 0 |
| Any serious TEAE | 9 | 7 | 7 | 5 | 11 |
| Any Causally Related TEAE | 9 | 7 | 7 | 5 | 11 |
| Any Causally Related Serious TEAE | 11 | 0 | 0 | 0 | 0 |
| Any Life Threatening Serious TEAE | 0 | 0 | 0 | 0 | 0 |
| Any TEAE of Dehydration | 0 | 0 | 0 | 0 | 0 |
| Any Death | 0 | 0 | 0 | 0 | 0 |
An AE was defined as any untoward medical occurrence in a subject or clinical trial subject administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product. Serious Adverse Event (SAE) is an adverse event that at any dose: Results in death, Is life-threatening (i.e. the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe), Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is considered to be an important medical event.
| Participants | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Any TEAE Leading to Discontinuation of Study Drug | 0 | 0 | 0 | 0 | 0 |
| Any TEAE Leading to Study Discontinuation | 0 | 0 | 0 | 0 | 0 |
Sternal skin conductance monitors (the Bahr MonitorTM) and the associated algorithm software were supplied by Simplex Scientific LLC (Middleton, USA). Participants were instructed to push a button on the skin conductance monitor when they sensed a hot flush when fitted with the monitor and then provide details of the hot flush in the continuous hot flush diary. Sternal skin conductance monitors were fitted on Day -1 (24 hours±1 hour prior to the planned study drug administration on Day 1) and remained in place until after the Day 7 24-hour assessments were completed (on Day 8). Refitted around 30 minutes prior to study drug administration on Day 14 and remained in place until after the 24-hour assessments were completed on Day 15.
| Hot flushes | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline ( Day -1) | 5.486 ± 7.148 | 8.680 ± 4.720 | 7.787 ± 6.153 | 3.200 ± 4.945 | 5.583 ± 7.242 |
| Change from Day -1 to Day 7 | -0.857 ± 6.794 | -3.986 ± 6.487 | -3.679 ± 4.670 | -2.197 ± 4.6090 | 0.000 ± 6.2450 |
| Change from Day -1 to day 14 | -0.139 ± 8.0619 | -2.642 ± 6.0682 | -2.913 ± 6.4202 | 0.600 ± 4.9261 | -2.908 ± 7.1204 |
Hot flush frequency and hot flush severity were obtained using the Hot Flush paper Diary. Subjects documented the number of individual hot flushes experienced and rated the severity of each on a scale of 1 to 3 (mild = 1, moderate = 2, severe = 3). The diaries were completed based on recall twice daily, in the morning and evening.
| Hot flushes | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline (Week -1) | 10.44 ± 3.866 | 12.70 ± 3.385 | 12.04 ± 3.606 | 10.22 ± 2.976 | 9.90 ± 2.107 |
| Change from Week -1 to Week 1 | -2.53 ± 3.645 | -1.91 ± 4.610 | -5.35 ± 5.153 | -6.36 ± 3.818 | -4.49 ± 2.801 |
| Change from Week -1 to Week 2 | -3.87 ± 4.179 | -3.07 ± 5.647 | -7.09 ± 4.915 | -8.62 ± 3.749 | -6.54 ± 3.453 |
Participants documented the number of individual hot flushes experienced and rated the severity of each on a scale of 1 to 3 (mild = 1, moderate = 2, severe = 3). The diaries were completed based on recall twice daily, in the morning and evening.
| Scores on a scale | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Week -1 | 2.32 ± 0.304 | 2.31 ± 0.319 | 2.20 ± 0.267 | 2.16 ± 0.379 | 2.19 ± 0.304 |
| Change from Week -1 to Week 1 | -0.30 ± 0.358 | -0.21 ± 0.276 | -0.23 ± 0.318 | -0.51 ± 0.542 | -0.34 ± 0.533 |
| Change from Week -1 to Week 2 | -0.34 ± 0.383 | -0.23 ± 0.242 | -0.36 ± 0.359 | -0.88 ± 0.656 | -0.42 ± 0.757 |
The hot flushes severity score was a composite of the frequency and severity of hot flushes, and was calculated as follows: number of mild hot flushes recorded on Day Y + number of moderate hot flushes recorded on Day Y × 2 + number of severe hot flushes recorded on Day Y × 3. Higher scores mean more severe hot flushes.
| Scores on a scale | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Week -1 | 28.06 ± 11.631 | 33.74 ± 8.875 | 32.52 ± 11.203 | 27.87 ± 7.720 | 26.75 ± 5.416 |
| Change from Week -1 to Week 1 | -6.99 ± 9.673 | -5.56 ± 10.907 | -14.48 ± 14.275 | -17.03 ± 9.996 | -12.23 ± 7.284 |
| Change from Week -1 to Week 2 | -10.67 ± 10.542 | -8.02 ± 13.031 | -19.19 ± 14.211 | -22.82 ± 9.505 | -17.55 ± 8.953 |
Subjects recorded each hot flush and its severity on a scale of 1 to 3 (mild = 1, moderate = 2, severe = 3) in the hot flush paper diary as they occurred during the day and night.
| Hot flushes | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Day 7 Change from Day -1 | -2.8 (-4.5 to -1.0) | -1.4 (-3.4 to 0.6) | -5.1 (-7.0 to -3.2) | -8.3 (-10.2 to -6.4) | -5.8 (-7.9 to -3.8) |
| Day 14 Change from Day -1 | -3.6 (-4.9 to -2.2) | -2.3 (-3.8 to -0.8) | -6.0 (-7.5 to -4.5) | -8.6 (-10.0 to -7.1) | -7.0 (-8.6 to -5.4) |
The number of NTAs secondary to hot flushes was the sum of the number of moderate and severe night-time hot flushes recorded the following morning (twice-daily hot flush diary) or recorded contemporaneously on the continuous diary.
| Night-time Awakenings | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Baseline (Week -1) | 4.51 ± 2.282 | 5.61 ± 1.785 | 5.41 ± 2.337 | 4.74 ± 2.111 | 4.76 ± 1.443 |
| Change from Week -1 to Week 1 | -0.77 ± 2.066 | -0.80 ± 2.448 | -2.52 ± 2.604 | -2.75 ± 2.335 | -2.07 ± 1.833 |
| Change from Week -1 to Week 2 | -1.44 ± 2.128 | -1.12 ± 2.665 | -3.00 ± 2.751 | -3.83 ± 2.008 | -3.02 ± 2.117 |
Change in Luteinizing Hormone(LH) AUC from time zero to 8 hours. Pre-dose samples for LH were taken within 30 minutes prior to dose administration.
| h*U/L | Placebo | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| Day -1 | 295.4 ± 82.64 | 295.5 ± 85.22 | 290.8 ± 85.83 | 309.5 ± 104.38 | 261.1 ± 65.53 |
| Change from Day -1 to Day 1 | 14.4 ± 31.33 | 4.7 ± 35.80 | -10.0 ± 21.90 | -31.1 ± 38.28 | -24.6 ± 32.36 |
| Change from Day -1 to Day 7 | 12.4 ± 57.46 | 22.9 ± 37.07 | 10.2 ± 20.49 | -12.1 ± 47.30 | -4.4 ± 33.43 |
Collected over Adverse events data were collected on or after first drug administration up to end of study (Day 21).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Comparator | 0/18 (0%) | 0/18 (0%) | 13/18 (72.2%) |
| 50 mg BAY3427080 | 0/15 (0%) | 0/15 (0%) | 7/15 (46.7%) |
| 100 mg BAY3427080 | 0/15 (0%) | 0/15 (0%) | 11/15 (73.3%) |
| 150 mg BAY3427080 | 0/15 (0%) | 0/15 (0%) | 10/15 (66.7%) |
| 300 mg BAY3427080 | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| Event | Placebo Comparator | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg BAY3427080 |
|---|---|---|---|---|---|
| SomnolenceNervous system disorders | 3/18 | 5/15 | 2/15 | 5/15 | 9/13 |
| HeadacheNervous system disorders | 3/18 | 0/15 | 5/15 | 1/15 | 6/13 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 5/18 | 2/15 | 6/15 | 5/15 | 2/13 |
| DiarrhoeaGastrointestinal disorders | 0/18 | 1/15 | 0/15 | 1/15 | 3/13 |
| Viral upper respiratory tract infectionInfections and infestations | 1/18 | 0/15 | 0/15 | 0/15 | 3/13 |
| Pelvic painReproductive system and breast disorders | 2/18 | 3/15 | 0/15 | 0/15 | 0/13 |
| Alanine aminotransferase increasedInvestigations | 0/18 | 0/15 | 2/15 | 0/15 | 0/13 |
| DyspepsiaGastrointestinal disorders | 2/18 | 0/15 | 0/15 | 1/15 | 0/13 |
| ConstipationGastrointestinal disorders | 0/18 | 0/15 | 1/15 | 0/15 | 1/13 |
| FlatulenceGastrointestinal disorders | 0/18 | 0/15 | 0/15 | 0/15 | 1/13 |
| Age, Continuous(Years) | Placebo Comparator | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg of BAY3427080 | Total |
|---|---|---|---|---|---|---|
| Mean | 55.2 ± 4.08 | 55.9 ± 5.57 | 55.3 ± 5.43 | 56.7 ± 4.37 | 53.8 ± 3.88 | 55.4 ± 4.67 |
| Sex: Female, Male(Participants) | Placebo Comparator | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg of BAY3427080 | Total |
|---|---|---|---|---|---|---|
| Female | 18 | 15 | 15 | 15 | 13 | 76 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Comparator | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg of BAY3427080 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 13 | 10 | 8 | 10 | 9 | 50 |
| Not Hispanic or Latino | 5 | 5 | 7 | 5 | 4 | 26 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Comparator | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg of BAY3427080 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 4 | 4 | 2 | 2 | 14 |
| White | 16 | 11 | 11 | 13 | 11 | 62 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Weight(kg) | Placebo Comparator | 50 mg BAY3427080 | 100 mg BAY3427080 | 150 mg BAY3427080 | 300 mg of BAY3427080 | Total |
|---|---|---|---|---|---|---|
| Mean | 73.25 ± 10.11 | 70.85 ± 11.82 | 73.47 ± 14.93 | 72.10 ± 7.10 | 72.73 ± 12.05 | 72.48 ± 11.20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Ran from Aug 2016 to primary completion in Mar 2017, 7 months.
Results were first posted in Feb 2021, 3 years 10 months after primary completion. A results delay was requested in Oct 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elinzanetant